Sanofi
SNYNF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.30 | 0.06 | 0.06 | -0.51 |
| FCF Yield | 0.00% | 0.00% | 1.66% | 0.00% |
| EV / EBITDA | 25.66 | 56.31 | 50.13 | 222.39 |
| Quality | ||||
| ROIC | 2.75% | 1.20% | 1.66% | 0.90% |
| Gross Margin | 74.09% | 72.13% | 72.76% | 68.69% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 0.17% | 0.56% | -0.91% | 0.06% |
| Free Cash Flow Growth | 0.00% | -100.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.05 | 3.67 | 4.71 | 18.59 |
| Interest Coverage | 15.96 | 16.94 | 10.73 | 12.34 |
| Efficiency | ||||
| Inventory Turnover | 0.14 | 0.31 | 0.13 | 0.24 |
| Cash Conversion Cycle | 69.37 | 145.30 | 11.08 | 158.27 |